Insider Selling: Beta Bionics (NASDAQ:BBNX) Insider Sells $680,620.20 in Stock

Beta Bionics, Inc. (NASDAQ:BBNX) insider Mark Hopman sold 36,870 shares of the company’s stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $18.46, for a total value of $680,620.20. Following the transaction, the insider directly owned 87,157 shares in the company, valued at $1,608,918.22. The trade was a 29.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mark Hopman also recently made the following trade(s):

• On Wednesday, September 2nd, Mark Hopman sold 5,327 shares of Beta Bionics stock. The stock was sold at an average price of $19.11, for a total value of $101,798.97.
• On Wednesday, June 24th, Mark Hopman sold 1,258 shares of Beta Bionics stock. The stock was sold at an average price of $15.01, for a total value of $18,882.58.

Beta Bionics Trading Down 4.8%

NASDAQ:BBNX traded down $0.83 on Thursday, hitting $16.59. 957,710 shares of the company’s stock traded hands, compared to its average volume of 1,143,668. Beta Bionics, Inc. has a 1 year low of $8.80 and a 1 year high of $32.71. The firm has a 50-day moving average price of $17.30 and a 200-day moving average price of $13.76. The company has a market cap of $746.38 million, a PE ratio of -10.05 and a beta of 3.37.

Beta Bionics (NASDAQ:BBNX) last issued its earnings results on Wednesday, July 29th. The company reported ($0.53) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. The company had revenue of $32.01 million for the quarter. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%. On average, research analysts forecast that Beta Bionics, Inc. will post -2.1 EPS for the current fiscal year.

Institutional Investors Weigh In On Beta Bionics

Several large investors have recently made changes to their positions in the company. Summit Securities Group LLC bought a new position in Beta Bionics during the fourth quarter valued at approximately $52,000. Caitong International Asset Management Co. Ltd lifted its stake in Beta Bionics by 1,075.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock valued at $61,000 after acquiring an additional 1,818 shares during the last quarter. Strs Ohio bought a new stake in Beta Bionics in the first quarter worth approximately $29,000. Legal & General Group Plc bought a new stake in Beta Bionics in the second quarter worth approximately $62,000. Finally, CIBC Private Wealth Group LLC increased its stake in shares of Beta Bionics by 630,000.0% during the 4th quarter. CIBC Private Wealth Group LLC now owns 6,301 shares of the company’s stock worth $192,000 after purchasing an additional 6,300 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on BBNX shares. William Blair initiated coverage on shares of Beta Bionics in a research report on Friday, August 21st. They issued a “market perform” rating for the company. Weiss Ratings upgraded shares of Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 18th. Truist Financial boosted their price target on shares of Beta Bionics from $18.00 to $22.00 and gave the company a “buy” rating in a report on Monday, July 13th. Bank of America dropped their price target on shares of Beta Bionics from $23.00 to $11.00 and set a “neutral” rating on the stock in a research note on Monday, May 18th. Finally, UBS Group initiated coverage on Beta Bionics in a report on Tuesday, July 28th. They set a “buy” rating and a $22.00 price objective for the company. Seven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Beta Bionics presently has a consensus rating of “Moderate Buy” and an average price target of $20.10.

Beta Bionics News Roundup

Here are the key news stories impacting Beta Bionics this week:

• Neutral Sentiment: Several law firms reminded investors that November 3, 2026 is the deadline to seek appointment as lead plaintiff in a federal securities class action filed in the U.S. District Court for the Central District of California. The proposed class covers investors who purchased Beta Bionics securities from July 30, 2025, through February 24, 2026. Johnson Fistel investor alert
• Negative Sentiment: The lawsuit alleges that Beta Bionics and certain officers misled investors about quality and safety issues involving its iLet insulin pump. According to the allegations, company filings characterized an FDA Warning Letter as identifying quality-management-system “non-conformities” while failing to disclose the extent of unreported iLet complaints, including complaints allegedly involving life-threatening hypoglycemia. These claims have not been proven in court. SueWallSt shareholder alert
• Negative Sentiment: The complaints further allege that analyst commentary remained favorable after the FDA Warning Letter because it relied on company statements that minimized the issue. If the claims succeed, Beta Bionics could face financial damages, legal expenses, regulatory scrutiny and reputational harm, creating additional uncertainty for the loss-making medical-device company. Levi and Korsinsky shareholder alert

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.